Hospitals and cancer centres at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

47 hospitals and cancer centres are at ISLB 2026 — 68 presentations on the program. Most represented: Princess Margaret Cancer Centre (4 on the program), IRCCS Ospedale Policlinico San Martino (3 on the program), IRST Dino Amadori (3 on the program). 24 of them have their own page in this guide. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–11 of 47 organizations

Organization	ISLB 2026 Attendance
Princess Margaret Cancer Centre Toronto, Canada
uhn.ca Hospitals & cancer centres Cancer centre of University Health Network in Toronto, for cancer care, research and education.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sun Nov 8 1:30pm–3:00pm Tumor Type Related Clinical use Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related Multimodal Assays in HN/Perspectives from Radiation Oncology Clinical use Talk Sun Nov 8 3:45pm–5:15pm Part of Awards Lecture One Drop at a Time – Integrating Liquid Biopsy into Routine Practice Poster Part of Poster sessions Cell-free DNA Hydroxymethylation Profiling in Treatment-naive and Relapsed SCLC ctDNA & MRD Poster Part of Poster sessions Bronchoalveolar Lavage to Accelerate Time to Molecular Diagnosis in Early-stage Lung Cancer Pre-analytics · Clinical use
IRCCS Ospedale Policlinico San Martino Genoa, Italy
ospedalesanmartino.it Hospitals & cancer centres Public research hospital in Genoa and teaching hospital of the University of Genoa.	Poster Part of Poster sessions Clonal Hematopoiesis in Early Breast Cancer: A Pilot Study on Treatment Toxicity and Clinical Outcomes Clinical use Collaborators: Fondazione Edo ed Elvo Tempia Poster Part of Poster sessions Plasma and Pleural Effusion Profiling Reveals Histotype-related Immune Patterns in Pleural Mesothelioma Clinical use · Pre-analytics Poster Part of Poster sessions Role of Soluble TIM3 in Developing Acquired Resistance in Metastatic Non-small-cell Lung Cancer Patients Undergoing First-line Immune Checkpoint Inhibitor-based Therapy Clinical use · New analytes
IRST Dino Amadori Meldola, Italy
irst.emr.it Hospitals & cancer centres Cancer hospital and research institute in Meldola, in Italy's Romagna area.	Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Molecular Profiling of Bile-derived DNA: New Perspectives for the Diagnosis and Management of Biliopancreatic Tumors Poster Part of Poster sessions Longitudinal ctDNA Profiling Reveals Molecular Evolution and Resistance Mechanisms in BRAFV600E-mutant Metastatic Colorectal Cancer ctDNA & MRD · Clinical use Poster Part of Poster sessions Plasma and Tissue Assessment of Homologous Recombination Deficiency-related Genomic Instability in Prostate Cancer Clinical use · ctDNA & MRD
Mayo Clinic Rochester, MN
mayoclinic.org Hospitals & cancer centres Non-profit academic medical center with campuses in Minnesota, Arizona and Florida, providing patient care, research and education.	Talk Sun Nov 8 9:30am–11:00am Part of Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures Non-invasive Profiling of the Tumor Microenvironment with Spatial Ecotypes New analytes Poster Part of Poster sessions Therapeutic Plasma Exchange as a Window into cfDNA Kinetics ctDNA & MRD Poster Part of Poster sessions Family-resolved Methylation Uncovers Cancer Signal Hidden in Plasma Cell-free DNA Repetitive Elements Early detection · ctDNA & MRD
Vall d'Hebron University Hospital Barcelona, Spain
vallhebron.com Hospitals & cancer centres Public university hospital in Barcelona, Spain, whose campus includes the Vall d'Hebron Institute of Oncology.	Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors When Tissue Falls Short: The Case for ctDNA in Detecting Emergent Resistance Mutations Industry hosted by MSD Clinical use · ctDNA & MRD Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Bringing ctDNA into Routine Care: Lessons from mCRPC Industry hosted by MSD Clinical use · ctDNA & MRD Poster Part of Poster sessions Harmonizing Plasma ESR1 Testing Across Spain: Results from the First Nationwide Multicenter Comparison of Commercial PCR Assays Pre-analytics Collaborators: Hospital del Mar
Ohio State University Comprehensive Cancer Center Columbus, OH
cancer.osu.edu Hospitals & cancer centres NCI-designated comprehensive cancer center of Ohio State University in Columbus, including its dedicated cancer hospital.	Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Chair Welcome and Framing Industry hosted by MSD Clinical use · ctDNA & MRD Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Opening Perspective: Redefining the Clinical Role of ctDNA in Solid Tumors Industry hosted by MSD Clinical use · ctDNA & MRD Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Panel Discussion: What will it take to Enable Frontline ctDNA Decision-making? Industry hosted by MSD Clinical use · ctDNA & MRD Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Closing Industry hosted by MSD Clinical use · ctDNA & MRD Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sat Nov 7 4:00pm–5:30pm Molecular Tumor Board Clinical use
DU Dexeus University Hospital Barcelona, Spain
Hospitals & cancer centres Private university hospital in Barcelona; houses the Pangaea Oncology molecular laboratory.	Session Sun Nov 8 9:30am–11:00am Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures New analytes Talk Sun Nov 8 9:30am–11:00am Part of Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures RNA-based Assays in Liquid Biopsy New analytes Session Mon Nov 9 10:00am–11:30am Preferred Oral Abstract Session Poster Part of Poster sessions Plasma Immune Gene Expression Profiling in NSCLC Patients from the SPACETIME Cohort New analytes Poster Part of Poster sessions Longitudinal Plasma-based Genomic and Transcriptomic Profiling Identifies Early Molecular Changes During KRAS G12C Inhibitor Treatment in Lung Adenocarcinoma Clinical use · ctDNA & MRD
ASST Papa Giovanni XXIII Bergamo, Italy
asst-pg23.it Hospitals & cancer centres Public hospital trust in Bergamo running the Papa Giovanni XXIII hospital.	Poster Part of Poster sessions Longitudinal ctDNA Methylation Profiling Reveals Treatment Response and Persistent Molecular Disease in Peripheral T-Cell Lymphoma ctDNA & MRD Collaborators: Humanitas Research Hospital Poster Part of Poster sessions Targeted Cell-free DNA Methylation Profiling Discriminates Breast-cancer Cases from Healthy Controls and Tracks Clinical and Molecular Features Early detection · ctDNA & MRD Collaborators: Humanitas Research Hospital
European Institute of Oncology (IEO) Milan, Italy
ieo.it Hospitals & cancer centres Private cancer hospital and research institute in Milan.	Session Sat Nov 7 4:00pm–5:30pm Workshop Biological Fluids: Pre-analytical Issues Pre-analytics Session Sun Nov 8 1:30pm–3:00pm Tumor Type Related Clinical use
Hospital Clínic de Barcelona Barcelona, Spain
clinicbarcelona.org Hospitals & cancer centres University hospital in Barcelona, linked to the IDIBAPS research institute.	Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related Melanoma and Liquid Biopsy Including Fragmentomics Clinical use Poster Part of Poster sessions Inferring Cell-type Signatures from cfDNA Fragmentation Profiles in Melanoma and Benign Melanocytic Lesions ctDNA & MRD · Early detection
II IRCCS Istituto Tumori Giovanni Paolo II Bari, Italy
Hospitals & cancer centres Public cancer research hospital in Bari.	Poster Part of Poster sessions Integration of Targeted Sequencing and Shallow Whole-genome Sequencing for Tumor Fraction Assessment in Lung and Breast Cancer Liquid Biopsy ctDNA & MRD Collaborators: Regina Elena National Cancer Institute Poster Part of Poster sessions Perioperative Plasma cfDNA Profiling in Colon Cancer: Feasibility and Exploratory Stage-associated ctDNA Analysis ctDNA & MRD